Stoke Therapeutics (STOK) Receivables - Other (2018 - 2026)

Stoke Therapeutics' Receivables - Other history runs 9 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 178.88% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 178.88% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 181.29% from the prior year.
• Receivables - Other slipped to $1.7 million in Q1 2026 per STOK's latest filing, from $2.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $2.0 million in Q4 2025 and bottomed at $11000.0 in Q1 2024.
• The 5-year median for Receivables - Other is $492000.0 (2023), against an average of $680529.4.
• Across the five-year window, Receivables - Other plunged 97.76% in 2024 and jumped 5409.09% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $588000.0 in 2022, then slumped by 89.12% to $64000.0 in 2023, then surged by 993.75% to $700000.0 in 2024, then soared by 181.29% to $2.0 million in 2025, then slipped by 14.17% to $1.7 million in 2026.
• Per Business Quant, the three latest STOK Receivables - Other figures stand at $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $1.6 million (Q3 2025).